Solventum

SOLV

Market cap $14.1B

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

EAGAN, Minn., July 15, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its second quarter fiscal 2026 financial results on Wednesday, August 5, 2026, after the U.S. financial markets close.

Solventum Corporation continues to trade at a noticeable discount, with shares showing resilience versus med-tech peers despite tepid growth expectations. Management targets 3–4% underlying revenue growth for 2026, with SOLV EPS likely at the high end of the $6.40–$6.60 range. Restructuring and portfolio optimization offer significant upside, as SOLV's business units lack natural synergies and could be divested.

The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

SOLV heads into 2026 balancing AI coding growth, cost savings, tariff pressure and a potential 2027 margin risk tied to its 3M supply deal.

Solventum Corporation (SOLV) Presents at Jefferies Global Healthcare Conference 2026 Transcript

EAGAN, Minn., May 27, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, Jun. 3, 2026, beginning at approximately 9:55 a.m.

Investors interested in Medical Services stocks are likely familiar with Solventum (SOLV) and HealthEquity (HQY). But which of these two stocks offers value investors a better bang for their buck right now?

Solventum Corporation (SOLV) Presents at Bank of America Global Healthcare Conference 2026 Transcript